Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This news section reviews recent findings in cancer research, including a study confirming finasteride's ability to reduce prostate cancer risk without raising mortality, but reports no new clinical results itself.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

This article discusses the long-term cardiovascular risks associated with polycystic ovary syndrome and highlights the greater effectiveness of lifestyle changes compared to metformin in preventing type 2 diabetes, but provides no new clinical outcomes.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This narrative review found that combined oral contraceptives remain the primary treatment for hirsutism and acne in women with PCOS, but highlighted the need for further research to refine therapeutic options given the variable efficacy and emerging treatments like GLP-1 receptor agonists.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study reports experience treating 140 women with hirsutism and other virilism signs using cyproterone acetate and ethinyl estradiol, focusing on those treated for over five months.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.

Anti-androgens are not better than birth control pills for PCOS, but can help with excess hair if pills don't work.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

This article reviews the effects of combined oral contraceptives on skin conditions and suggests prescribing guidelines for women with acne, as it reports no new clinical results.

Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

In this study, researchers found that finasteride inhibits progesterone synthesis by blocking cholesterol side-chain cleavage in mouse-derived MA-10 Leydig cells, but this effect may not be evident in human or rat cells.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

This article discusses the androgenicity of progestins used in hormonal contraceptives and its potential impact on female pattern hair loss, but reports no new clinical findings.

This study found that Hedgehog signaling likely contributes to cervical carcinogenesis, and while itraconazole reduced growth in mice, it did so through pathways other than inhibiting Hedgehog signaling.

This review discusses preclinical and clinical chemoprevention research for several cancers, noting challenges in effectiveness and toxicity, and emphasizes the need for further trials.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.